How are steroids used in leukocytapheresis (LCAP) for the treatment of ulcerative colitis?

Steroid Use with Leukocytapheresis (LCAP) in Ulcerative Colitis

Leukocytapheresis can be performed effectively without concurrent corticosteroids and may serve as a steroid-sparing strategy, particularly in steroid-dependent patients where it achieves steroid discontinuation in 60% of cases.

Key Clinical Scenarios

LCAP Without Steroids (Steroid-Naïve or Steroid-Refusing Patients)

LCAP monotherapy demonstrates robust efficacy without concurrent corticosteroids:

• Clinical remission achieved in 83% of patients who refused steroids, including both severe and moderately severe cases 1
• In steroid-naïve patients, LCAP showed equivalent efficacy to prednisolone (88.9% vs 80.0% clinical improvement) but with superior safety profile—zero major adverse effects with LCAP versus three major complications with steroids 2
• This approach is particularly valuable for patients where steroid adverse effects (osteoporosis, diabetes, growth retardation) preclude their use 1

LCAP for Steroid-Dependent Disease (Primary Indication)

Long-interval cytapheresis (LI-CAP) represents the optimal steroid-sparing strategy:

• 60% steroid discontinuation rate using LI-CAP protocol (one session every 2-3 weeks during entire steroid taper period) 3
• Mean prednisolone dose reduced from 17.3 mg to 2.3 mg daily (p=0.0003) 3
• Sustained steroid-free remission maintained in 66.7% at both 6 and 12 months 3
• In real-world practice, 36% of steroid-dependent patients achieved long-term steroid-free remission at 12 months, even after thiopurine failure in 69% 4

LCAP Combined with Steroids

When steroids are continued during LCAP:

• 80% improvement rate in active LCAP versus 33% with sham apheresis (p<0.05), confirming efficacy beyond placebo effect 5
• The protocol typically maintains stable steroid doses during initial LCAP sessions (first 2 weeks), then allows tapering 5

Practical Treatment Algorithm

For steroid-dependent UC:

1. Initiate LI-CAP: one session every 2-3 weeks
2. Begin gradual steroid taper concurrently
3. Continue LI-CAP throughout entire taper period
4. Target: complete steroid discontinuation by end of LI-CAP course

For active UC in steroid-refusing/contraindicated patients:

1. Offer LCAP monotherapy: once weekly for 4-10 sessions
2. Continue 5-ASA derivatives
3. Expect clinical response within 1 week, remission by course completion

For steroid-refractory disease:

• Per current guidelines, escalate to infliximab or cyclosporine rather than adding LCAP 6
• LCAP is not positioned as rescue therapy for steroid-refractory acute severe UC

Critical Caveats

• LCAP efficacy is independent of initial steroid dose, session frequency, or prior thiopurine/infliximab failure 4
• Greater CRP decrease correlates with higher remission probability 4
• Steroids are never appropriate for long-term maintenance regardless of LCAP use 7
• If no adequate response to oral corticosteroids within 2 weeks, advance to biologics/small molecules rather than prolonging steroid exposure 7

Safety Comparison

LCAP demonstrates superior safety versus steroids:

• No serious adverse effects in steroid-naïve comparison study 2
• Only minor hemoglobin decrease (1 g/dL) noted 1
• Contrast with steroid complications: infection risk, metabolic effects, bone loss 8

The evidence strongly supports LCAP as a legitimate steroid-sparing or steroid-replacement strategy, with the LI-CAP protocol specifically designed to facilitate complete steroid withdrawal in dependent patients 3.